Approval · Notice of Compliance 31470 · 2023

ZOLOFT: Notice of Compliance 31470

Issued August 22, 2023

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 31470
Date: August 22, 2023
Company: BGP Pharma ULCEtobicoke, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Administrative: Change in Product Ownership

Products in this notice

Brand	DIN	Status today
ZOLOFT	02132702	Marketed
ZOLOFT	01962817	Marketed
ZOLOFT	01962779	Marketed

Medicinal ingredients

SERTRALINE HYDROCHLORIDE 25 MG per CAP
SERTRALINE HYDROCHLORIDE 50 MG per CAP
SERTRALINE HYDROCHLORIDE 100 MG per CAP